
    
      In this study, it is planned to enroll at least 42 NSCLC patients who meet relevant criteria.
      This study includes dose escalation phase and extension phase of the combined therapy: three
      combined dose groups are planned in the dose escalation phase; the dose extension phase is
      divided into two cohorts.
    
  